Xencor to co-develop IL-15 therapies with Genentech

Xencor Inc. (NASDAQ:XNCR) will receive $120 million up front in a deal to co-develop its IL-15 cytokine therapeutics, including XmAb24306, with Genentech Inc.

The partners will evaluate combinations of XmAb24306 with products from Genentech's oncology portfolio. Clinical data has suggested immune-stimulating cytokine therapies, including those based on IL-15, could increase the efficacy of checkpoint inhibitors (see "POC for Cytokines")...